MIRAMAR, Fla., Jan. 17, 2020 (GLOBE NEWSWIRE) -- G
Post# of 36566
(Total Views: 333)
Posted On: 01/17/2020 2:10:06 PM
MIRAMAR, Fla., Jan. 17, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) today announced Call-in details for the upcoming investor conference call on Tuesday January 21, 2020 at 9:30 AM Eastern time.
The access information for the investor conference call is as follows:
Domestic US/Canada – 1-(866) 342-8588
Direct Toll / International - 1-(203) 518-9865,
Program Title: Generex Biotechnology Announces Investor Conference Call
Conference ID – 3654
Agenda:
Update on the 2:5 GNBT stock dividend and the 2:5 NuGenerex Immuno-Oncology (NGIO) stock dividend & the FINRA approval process
Share price review: Impact of irregular & illegal trading and plans to address wrongdoing
Go-forward plans to build and operate the Generex enterprise
Update on the progress toward the NuGenerex Immuno-Oncology (NGIO) spinout
Funding update
ALTuCELL closing update
As always, Generex President & Chief Executive Officer, Joseph Moscato welcomes questions from shareholders during the call.
The access information for the investor conference call is as follows:
Domestic US/Canada – 1-(866) 342-8588
Direct Toll / International - 1-(203) 518-9865,
Program Title: Generex Biotechnology Announces Investor Conference Call
Conference ID – 3654
Agenda:
Update on the 2:5 GNBT stock dividend and the 2:5 NuGenerex Immuno-Oncology (NGIO) stock dividend & the FINRA approval process
Share price review: Impact of irregular & illegal trading and plans to address wrongdoing
Go-forward plans to build and operate the Generex enterprise
Update on the progress toward the NuGenerex Immuno-Oncology (NGIO) spinout
Funding update
ALTuCELL closing update
As always, Generex President & Chief Executive Officer, Joseph Moscato welcomes questions from shareholders during the call.
(0)
(0)